{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:36Z","timestamp":1791169416537,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2321-3","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The choice of first-line Chronic Myelogenous Leukemia treatment"],"prefix":"10.1007","volume":"94","author":[{"given":"Carmen","family":"Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2321_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"2321_CR2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","volume":"47","author":"JM Goldman","year":"2010","unstructured":"Goldman JM (2010) Chronic myeloid leukemia: a historical perspective. Semin Hematol 47:302\u2013311","journal-title":"Semin Hematol"},{"key":"2321_CR3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758\u20133765","journal-title":"Blood"},{"key":"2321_CR4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et al (2011) Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 29:1634\u20131642","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2321_CR5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"2321_CR6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119:1981\u20131987","journal-title":"Blood"},{"key":"2321_CR7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","volume":"93","author":"R Hehlmann","year":"2008","unstructured":"Hehlmann R, Saussele S (2008) Treatment of chronic myeloid leukemia in blast crisis. Haematologica 93:1765\u20131769","journal-title":"Haematologica"},{"key":"2321_CR8","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU et al (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121:4175\u20134183","journal-title":"Blood"},{"key":"2321_CR9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561","journal-title":"J Natl Cancer Inst"},{"key":"2321_CR10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","volume":"112","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, O\u2019Brien S, Shan J et al (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837\u2013845","journal-title":"Cancer"},{"key":"2321_CR11","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444","journal-title":"Blood"},{"key":"2321_CR12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2321_CR13","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae)Chronic myelogenous leukemia version 3.2014. NCCN.org"},{"key":"2321_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"2321_CR15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.11172","volume":"92","author":"MC Muller","year":"2007","unstructured":"Muller MC, Saglio G, Lin F et al (2007) An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 92:970\u2013973","journal-title":"Haematologica"},{"key":"2321_CR16","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175","journal-title":"Leukemia"},{"key":"2321_CR17","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S et al (2011) The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118:4541\u20134546, quiz 759","journal-title":"Blood"},{"key":"2321_CR18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"key":"2321_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423","journal-title":"J Clin Oncol"},{"key":"2321_CR20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"2321_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"2321_CR22","first-page":"1680","volume":"118","author":"D Milojkovic","year":"2011","unstructured":"Milojkovic D, Ibrahim AR, Foroni L et al (2011) Assessment of BCR-ABL1 Transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with imatinib. ASH Ann Meet Abstr 118:1680","journal-title":"ASH Ann Meet Abstr"},{"key":"2321_CR23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353\u20131360","journal-title":"Blood"},{"key":"2321_CR24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"key":"2321_CR25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE et al (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123:2317\u20132324","journal-title":"Blood"},{"key":"2321_CR26","first-page":"3770","volume":"118","author":"PD Coutre le","year":"2011","unstructured":"le Coutre PD, Giles FJ, Pinilla-Ibarz J et al (2011) Nilotinib in imatinib-resistant or -intolerant patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study. ASH Ann Meet Abstr 118:3770","journal-title":"ASH Ann Meet Abstr"},{"key":"2321_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"2321_CR28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"key":"2321_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118:686\u2013692","journal-title":"Blood"},{"key":"2321_CR30","doi-asserted-by":"crossref","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E et al (2011) Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29:3173\u20133178","DOI":"10.1200\/JCO.2010.33.4169"},{"key":"2321_CR31","doi-asserted-by":"crossref","unstructured":"Guilhot J, Baccarani M, Clark RE et al (2012) Definitions, methodological, and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 119:5963\u20135971","DOI":"10.1182\/blood-2011-10-383711"},{"key":"2321_CR32","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.seminhematol.2009.01.011","volume":"46","author":"FJ Giles","year":"2009","unstructured":"Giles FJ (2009) New directions in the treatment of imatinib failure and\/or resistance. Semin Hematol 46:S27\u2013S33","journal-title":"Semin Hematol"},{"key":"2321_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543784.14.1.89","volume":"14","author":"SA Doggrell","year":"2005","unstructured":"Doggrell SA (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Invest Drugs 14:89\u201391","journal-title":"Expert Opin Invest Drugs"},{"key":"2321_CR34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94:1765\u20131769","journal-title":"Br J Cancer"},{"key":"2321_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/ehm.09.42","volume":"2","author":"G Keller","year":"2009","unstructured":"Keller G, Schafhausen P, Brummendorf TH (2009) Bosutinib: a dual SRC\/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Hematol 2:489\u2013497","journal-title":"Expert Rev Hematol"},{"key":"2321_CR36","doi-asserted-by":"crossref","unstructured":"Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM (2011) Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117:1800\u20131811","DOI":"10.1002\/cncr.25717"},{"key":"2321_CR37","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F et al (2009) Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114:4933\u20134938","journal-title":"Blood"},{"key":"2321_CR38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392\u2013397","journal-title":"J Clin Oncol"},{"key":"2321_CR39","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398\u2013404","journal-title":"J Clin Oncol"},{"key":"2321_CR40","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"2321_CR41","doi-asserted-by":"crossref","unstructured":"Saglio G, Hughes TP, Clark RE et al (2013) ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) In patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood 122:92","DOI":"10.1182\/blood.V122.21.92.92"},{"key":"2321_CR42","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"2321_CR43","doi-asserted-by":"crossref","unstructured":"Cortes J, Saglio G, Baccarani M et al (2014) Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood 124:152","DOI":"10.1182\/blood.V124.21.152.152"},{"key":"2321_CR44","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120:3898\u20133905","journal-title":"Blood"},{"key":"2321_CR45","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486\u20133492","journal-title":"J Clin Oncol"},{"key":"2321_CR46","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F et al (2013) Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27:1310\u20131315","journal-title":"Leukemia"},{"key":"2321_CR47","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"},{"key":"2321_CR48","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"2321_CR49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388","journal-title":"J Clin Oncol"},{"key":"2321_CR50","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S et al (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873\u20132878","journal-title":"Blood"},{"key":"2321_CR51","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","volume":"113","author":"F Castagnetti","year":"2009","unstructured":"Castagnetti F, Palandri F, Amabile M et al (2009) Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 113:3428\u20133434","journal-title":"Blood"},{"key":"2321_CR52","first-page":"2149","volume":"108","author":"J Cortes","year":"2006","unstructured":"Cortes J, Giles F, Salvado AJ et al (2006) Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT trial study group. ASH Ann Meet Abstr 108:2149","journal-title":"ASH Ann Meet Abstr"},{"key":"2321_CR53","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1200\/jco.2006.24.18_suppl.6535","volume":"24","author":"E Aoki","year":"2006","unstructured":"Aoki E, Kantarjian H, O'Brien S et al (2006) High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. J Clin Oncol (Meet Abstr) 24:6535","journal-title":"J Clin Oncol (Meet Abstr)"},{"key":"2321_CR54","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL et al (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy. Blood 112:3965\u20133973","journal-title":"Blood"},{"key":"2321_CR55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol Off J Am Soc Clin Oncol 28:424\u2013430","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2321_CR56","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F et al (2009) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113:4497\u20134504","journal-title":"Blood"},{"key":"2321_CR57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","volume":"164","author":"MW Deininger","year":"2014","unstructured":"Deininger MW, Kopecky KJ, Radich JP et al (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223\u2013232","journal-title":"Br J Haematol"},{"key":"2321_CR58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","volume":"93","author":"F Palandri","year":"2008","unstructured":"Palandri F, Iacobucci I, Castagnetti F et al (2008) Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 93:770\u2013774","journal-title":"Haematologica"},{"key":"2321_CR59","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521","journal-title":"N Engl J Med"},{"key":"2321_CR60","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B et al (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118:3228\u20133235","journal-title":"Blood"},{"key":"2321_CR61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cncr.25438","volume":"117","author":"J Cortes","year":"2011","unstructured":"Cortes J, Quintas-Cardama A, Jones D et al (2011) Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117:572\u2013580","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2321-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2321-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:23:54Z","timestamp":1598851434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2321-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":61,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2321-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}